SCHEMBL6091808

SCHEMBL6091808

N[C@@H]1CCN2c3c(cccc31)C(=O)N[C@H]2c1ccc(-n2ccnc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 11/20 0.37
PDE3A Q14432 11/20 0.37
CHRNA7 P36544 1/20 0.37
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
PDE2A O00408 2/20 0.35
PDE1A P54750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092168 1.00 PDE3B (0.37) PDE3BPDE3ACHRNA7HTR2AHTR2C
SCHEMBL6089161 0.82 PDE3B (0.40) PDE3BPDE3ACHRNA7HTR2AHTR2C
SCHEMBL6091992 0.81 PARP1 (0.35) HTR2AHTR2CHTR2B
SCHEMBL6089696 0.81 TNKS2 (0.39) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL6090392 0.81 TNKS2 (0.39) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL6090413 0.81 PARP1 (0.35) HTR2AHTR2CHTR2B
SCHEMBL6090730 0.81 TNKS2 (0.35) HTR2AHTR2CHTR2BPDE4DLMNA
SCHEMBL6089791 0.81 TNKS2 (0.35) HTR2AHTR2CHTR2BPDE4DLMNA
SCHEMBL6092215 0.80 MEN1 (0.39) HTR2AHTR2CHTR2BMAPT
SCHEMBL6092437 0.80 ALDH1A1 (0.45) HTR2CHTR2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 PDE3B 2362/4885PDE3A 2325/4885CHRNA7 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.